Quit Genius, a San Francisco, CA-baserd personalized digital therapeutic for addictions, raised a further $11m in Series A funding.
The round was led by Octopus Ventures, with participation from Y Combinator, Startup Health, Triple Point Ventures, Serena Ventures and Venus Williams, amongst others.
The company intends to use the funds to expand its therapeutic programs beyond cigarette and vaping addiction to include alcohol and substance abuse, as well as increase its presence in the US, which is currently experiencing an opioid ‘epidemic’. Quit Genius provides a personalized digital program that includes cognitive behavioral therapy, expert coaching, a connected breath sensor and access to proven medication.
Founded by three medical doctors and led by Yusuf Sherwani, CEO, the company’s initial focus has been tobacco and vaping use. At present, Quit Genius works predominantly with self-insured employers and health plans to help lower healthcare costs, while improving employee satisfaction. The company already reaches over 700,000 enrolled participants globally, working with enterprise clients across the US, Canada and the UK.